ClinicalTrials.Veeva

Menu
L

Linear Clinical Research | Perth, Australia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tislelizumab
Pembrolizumab
ZE46-0134
SHR-1316
Docetaxel
ALS-002158
SLN360
Elranatamab
ARO-APOC3
Sildenafil

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

20 of 49 total trials

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

The goal of this clinical trial is to learn about IOS-1002 in patients with solid tumors.The main questions it aims to answer are:* To determine the...

Enrolling
Solid Tumor, Adult
Drug: IOS-1002
Drug: IOS-1002 + KEYTRUDA® (pembrolizumab)

* To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer the...

Active, not recruiting
Advanced or Metastatic Solid Tumors
Drug: Pembrolizumab
Drug: ERAS-601

The primary aim of this study is to evaluate safety and tolerability data when SRSD107 is administered as single SC injections to healthy participant...

Enrolling
Thrombosis
Drug: Placebo
Drug: SRSD107

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with sel...

Enrolling
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Acute Myeloid Leukemia (AML)
Drug: Zanubrutinib
Drug: PRT2527

To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors* To evaluate...

Enrolling
Advanced or Metastatic Solid Tumors
Drug: Trametinib
Drug: Naporafenib

The primary purpose of this study is to assess the safety and tolerability of single ascending doses of GS1-144 in healthy participants in Part 1 and...

Enrolling
Vasomotor Symptoms
Adult Healthy Volunteers
Drug: Placebo
Drug: GS1-144

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NR...

Enrolling
Melanoma
Solid Tumor, Adult
Drug: KIN-2787 and binimetinib
Drug: KIN-2787

This is a clinical study aiming to assess pharmacokinetics, pharmacodynamics and preliminary efficacy of ZE46-0134 in patients with FLT3 mutated Rela...

Not yet enrolling
AML With Gene Mutations
Drug: ZE46-0134

This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. T...

Enrolling
Lymphoma, Non-Hodgkin
Drug: DZD8586

This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacoki...

Enrolling
Breast Cancer
Gastric Cancer
Drug: IKS014

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunog...

Enrolling
B-cell Non-Hodgkin Lymphoma
B-cell Lymphoma
Drug: IKS03

The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclo...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Pomalidomide

This is a phase 1, randomized, double-blind, placebo-controlled study. The objective of this study is to evaluate the safety, tolerability, and PK pr...

Active, not recruiting
MRI
Drug: HRS-9231or matching placebo

Randomized, double-blind, placebo-controlled, dose-escalation Phase I safety study of inhaled N-IP-00001, to determine tolerability and safety in hea...

Not yet enrolling
Healthy
Drug: 0.9% NaCl isotonic saline solution
Drug: N-IP-00001 inhalation solution

The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanc...

Active, not recruiting
Advanced Solid Tumor
Non Small Cell Lung Cancer
Drug: BGB-A445
Drug: tislelizumab

This is a phase 1b multi-center, open-label study of HMBD-001 in combination with docetaxel with or without cetuximab in participants with locally ad...

Enrolling
Advanced Head and Neck Squamous Cell Carcinoma
Cervical Squamous Cell Carcinoma
Drug: HMBD-001
Drug: Cetuximab

This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1...

Enrolling
Locally Advanced Solid Tumor
Metastatic Solid Tumor
Drug: Gemcitabine
Drug: Nab-paclitaxel

This is an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of BGB-A425 and/or LBL-007 with tislel...

Enrolling
Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2
Drug: Tislelizumab
Drug: LBL-007

This is a clinical study aiming to assess pharmacokinetics and biomarker evidence of ZE46-0134 efficacy in Healthy Volunteers after single and multip...

Enrolling
AML
Drug: Rabeprazole, 20mg oral
Drug: ZE46-0134 or placebo

This is a dose escalation, Phase 1 study of ABN401 in patients with advanced solid tumors, refractory metastatic disease, or refractory locally advan...

Enrolling
Advanced Solid Tumors
Drug: ABN401- Escalation Phase
Drug: ABN401- Expansion Phase

Trial sponsors

A
BeiGene logo
Arrowhead Pharmaceuticals logo
E
H
I
E
A
A
Agenus logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems